An interventional study of biopsy and therapeutic conventional surgery in Bladder Cancer, sponsored by Roei Medical Technologies Ltd.. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2013-03-26.
Sponsored by Roei Medical Technologies Ltd. · Not applicable, Interventional, and Treatment
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
PURPOSE: This clinical trial is studying how well the loop resectoscope works in treating patients with bladder cancer or benign prostatic hyperplasia who are undergoing transurethral resection.
OBJECTIVES:
OUTLINE: This is an open-label, pilot study.
Patients undergo transurethral resection using the Roei loop resectoscope. Surgeon satisfaction with the Roei loop resectoscope is measured by a self-assessment questionnaire. The quality of specimens submitted for histological study are also assessed.
PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
1,616 studies on the registry are indexed under Urinary Bladder Neoplasms; 421 are open to participants now.
This study's planned enrollment of 24 is below the median of 60 across 1,163 interventional studies indexed under Urinary Bladder Neoplasms.
Browse Urinary Bladder Neoplasms studies →This is the only study on the registry with Roei Medical Technologies Ltd. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Surgeon satisfaction with usage of Roei loop resectoscope measured by a questionnaire after the surgical procedure
This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.